ヒト免疫不全ウイルス（HIV）：疫学予測（～2033年）

当レポートでは、主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）におけるヒト免疫不全ウイルス（HIV）について調査分析し、危険因子や併存疾患、過去の疫学的動向に関する情報を提供しています。

目次

第1章 ヒト免疫不全ウイルス：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
  • HIVの総有病率
  • HIVの診断有病率
  • HIVの診断罹患率
• 主要7市場の予測手法
• HIVの疫学的予測（2023年～33年）
  • HIVの総有病者数
  • HIVの診断有病者数
  • HIVの診断有病者数：年齢別
  • HIVの診断有病者数：性別
  • 重複感染を伴うHIVの診断有病者数
  • 抗レトロウイルス治療を受けているHIVの診断有病者数
  • HIVの診断罹患者数
  • HIVの診断罹患者数：年齢別
  • HIVの診断罹患者数：性別
  • 曝露前予防を受けている予防集団
  • 曝露後予防を受けている予防集団
• 議論
  • 疫学的予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of newly added data types
• Table 2: Summary of updated data types
• Table 3: Risk factors and comorbidities for HIV

List of Figures

• Figure 1: 7MM, total prevalent cases of HIV, both sexes, N, all ages, 2023 and 2033
• Figure 2: 7MM, diagnosed prevalent cases of HIV, both sexes, N, all ages, 2023 and 2033
• Figure 3: 7MM, diagnosed incident cases of HIV, both sexes, N, all ages, 2023 and 2033
• Figure 4: 7MM, total prevalence of HIV, both sexes, %, all ages, 2013-33
• Figure 5: 7MM, diagnosed prevalence of HIV, both sexes, %, all ages, 2013-33
• Figure 6: 7MM, diagnosed incidence of HIV, both sexes, %, all ages, 2013-33
• Figure 7: 7MM, sources used to forecast the total prevalent cases of HIV
• Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of HIV
• Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of HIV with HBV or HCV coinfection
• Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of HIV on ART
• Figure 11: 7MM, sources used to forecast the diagnosed incident cases of HIV in the 7MM
• Figure 12: 7MM, sources used to forecast the population on PrEP in the 7MM
• Figure 13: 7MM, sources used to forecast the PEP coverage in the 7MM
• Figure 14: 7MM, total prevalent cases of HIV, N, both sexes, all ages, 2023
• Figure 15: 7MM, diagnosed prevalent cases of HIV, N, both sexes, all ages, 2023
• Figure 16: 7MM, diagnosed prevalent cases of HIV by age, N, both sexes, 2023
• Figure 17: 7MM, diagnosed prevalent cases of HIV by sex, N, all ages, 2023
• Figure 18: 7MM, diagnosed prevalent cases of HIV with HBV/HCV coinfection, N, both sexes, all ages, 2023
• Figure 19: 7MM, diagnosed prevalent cases of HIV on ART, N, both sexes, all ages, 2023
• Figure 20: 7MM, diagnosed incident cases of HIV, N, both sexes, all ages, 2023
• Figure 21: 7MM, diagnosed incident cases by age, N, both sexes, 2023
• Figure 22: 7MM, diagnosed incident cases of HIV by sex, all ages, 2023
• Figure 23: 7MM, prophylactic population on PrEP, N, both sexes, all ages, 2023
• Figure 24: 7MM, prophylactic population on PEP, N, both sexes, all ages, 2023

Discovered in 1983, human immunodeficiency virus (HIV) is an RNA virus that reverse transcribes itself into the human host's DNA and produces lifelong infection. HIV primarily infects cells with CD4+ antigen, such as T-cells and macrophages, two essential white blood cell types (Swinkels et al., 2024) During the acute stage of infection, HIV destroys these CD4+ cells, which allows for the transmission of the virus, opportunistic infections, and the eventual development of AIDS (NIH, 2021; NIH, 2024). Symptoms occur within four weeks of exposure and include flu-like symptoms such as fever, fatigue, muscle pain, rash, and headache. Symptoms last approximately 18 days before the onset of chronic infection (Swinkels et al., 2024). Chronic HIV infection is largely asymptomatic. If untreated, it will develop into AIDS after approximately 10 years. AIDS is defined by a CD4+ cell count below 200 cells per cubic millimeter of blood or the presence of AIDS-defining conditions, such as pulmonary candidiasis, primary lymphoma of the brain, or Kaposi sarcoma (NIH, 2024; Swinkels et al., 2024)

HIV transmission occurs via contact with bodily fluids, such as can occur during unprotected sex, childbirth and breastfeeding, intravenous drug use, and needle stick (NIH, 2024). At-risk populations for HIV include people who inject drugs (PWID), children of an HIV-positive birthing person, men who have sex with men (MSM), sex workers, institutionalized people such as prisoners, and gender-diverse people (Swinkels et al., 2024).

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for HIV in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases, diagnosed prevalent cases, and diagnosed incident cases of HIV segmented by age (<18 years, 18-29 years, and by 10-year age groups for 30 years up to 80 years and older) and sex. Additionally, this report provides a 10-year epidemiological forecast for the diagnosed prevalent cases of HIV on antiretroviral therapy (ART), segmented by age (<13 years, 13-17 years, and 18 years and older), as well as the diagnosed prevalent cases of HIV coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV). Coverage of the prophylactic population by pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is also provided throughout the forecast.

Reasons to Buy

The HIV Epidemiology series will allow you to -

• Develop business strategies by understanding the trends shaping and driving the global HIV markets.
• Quantify patient populations in the global HIV markets to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HIV therapeutics in each of the markets covered.
• Understand magnitude of the HIV population by age, sex, ART coverage, HBV/HCV co-infection, as well as PrEP and PEP coverage of the prophylactic population.

Table of Contents

Table of Contents

• About GlobalData

1 Human Immunodeficiency Virus: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
  • 2.3.1 Total prevalence of HIV
  • 2.3.2 Diagnosed prevalence of HIV
  • 2.3.3 Diagnosed incidence of HIV
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Sources not used
  • 2.4.3 Forecast assumptions and methods
  • 2.4.4 Total prevalent cases of HIV
  • 2.4.5 Diagnosed prevalent cases of HIV
  • 2.4.6 Diagnosed prevalent cases of HIV with hepatitis B virus/hepatitis C virus coinfection
  • 2.4.7 Diagnosed prevalent cases of HIV on antiretroviral treatment
  • 2.4.8 Diagnosed incident cases of HIV
  • 2.4.9 Prophylactic population on pre-exposure prophylaxis
  • 2.4.10 Prophylactic population on post-exposure prophylaxis
• 2.5 Epidemiological forecast for HIV (2023-33)
  • 2.5.1 Total prevalent cases of HIV
  • 2.5.2 Diagnosed prevalent cases of HIV
  • 2.5.3 Age-specific diagnosed prevalent cases of HIV
  • 2.5.4 Sex-specific diagnosed prevalent cases of HIV
  • 2.5.5 Diagnosed prevalent cases of HIV with coinfection
  • 2.5.6 Diagnosed prevalent cases of HIV on antiretroviral treatment
  • 2.5.7 Diagnosed incident cases of HIV
  • 2.5.8 Age-specific diagnosed incident cases of HIV
  • 2.5.9 Sex-specific diagnosed incident cases of HIV
  • 2.5.10 Prophylactic population on pre-exposure prophylaxis
  • 2.5.11 Prophylactic population on post-exposure prophylaxis
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Analysis and Intelligence
  • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
• Contact Us